Brief: Vaxcyte Completes Phase 2 Study Enrollment Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease in Infants

Vaxcyte

04/03/2024 15:11

March 4 (Reuters) - Vaxcyte Inc  PCVX.O :
    * VAXCYTE COMPLETES ENROLLMENT OF PHASE 2 STUDY EVALUATING
VAX-24
FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN
INFANTS
    * VAXCYTE INC - EXPECTS TO ANNOUNCE TOPLINE SAFETY,
TOLERABILITY
AND IMMUNOGENICITY DATA FROM PRIMARY IMMUNIZATION SERIES BY END
OF Q1 OF 2025
    * VAXCYTE INC - EXPECTS TO ANNOUNCE TOPLINE DATA FROM
BOOSTER DOSE
BY END OF 2025

Source text for Eikon:  ID:nGNX2BTswx 
Further company coverage:  PCVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))